<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723983</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-15-NP101-011</org_study_id>
    <nct_id>NCT00723983</nct_id>
  </id_info>
  <brief_title>Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period</brief_title>
  <acronym>NP101-011</acronym>
  <official_title>A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuPathe Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics of NP101 with a currently approved oral formulation of&#xD;
      Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a&#xD;
      non-migraine period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the pharmacokinetics of NP101 with a currently approved formulation of Imitrex in migraine subjects during an acute migraine attack and during a non-migraine period.</measure>
    <time_frame>PK samples at pre and 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12 and 24 hours post each dose/period for Periods 1, 2, 3, and 4 [24 hour PK will not be done for Periods 5 and 6]</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject dosed with oral sumatriptan succinate during an acute migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject dosed with oral sumatriptan during a non-migraine period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3 and Period 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject dosed with NP101 during an acute migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 4 and Period 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject dosed with NP101 study patch during a non-migraine period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan succinate</intervention_name>
    <description>Sumatriptan succinate 50 mg taken orally</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP101 Study Patch</intervention_name>
    <description>NP101 study patch 4 hour application</description>
    <arm_group_label>Period 3 and Period 6</arm_group_label>
    <arm_group_label>Period 4 and Period 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male and female subjects, between the ages of 18 to 65 years.&#xD;
&#xD;
          -  Subjects with a diagnosis of migraine headache, with or without aura, as defined in&#xD;
             the ICHD-II, and the diagnosis was made before the age of 50.&#xD;
&#xD;
          -  The majority of a subject's headaches during a migraine attack are moderate to severe&#xD;
             in intensity.&#xD;
&#xD;
          -  Subject has history of regularly occuring migraines, accompanied by nausea or&#xD;
             vomiting.&#xD;
&#xD;
          -  Subject has at least one year history of migraine based upon subject testimony.&#xD;
&#xD;
          -  Subject will be judged to be in good health, based upon the results of a medical&#xD;
             history, physical examination, vital signs, ECG and laboratory profile.&#xD;
&#xD;
          -  Subjects must voluntarily sign and date and Informed Consent agreement approved by an&#xD;
             IRB.&#xD;
&#xD;
          -  Subject must have a negative drug screen and re-screen.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative pregnancy test at&#xD;
             Screening and Re-Screening.&#xD;
&#xD;
          -  Subject has two acceptable patch application sites.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has or plans to start stop, or change treatment (including dose change) of any&#xD;
             medication within one month prior to the subject screening date and through the end of&#xD;
             study.&#xD;
&#xD;
          -  Subject has less than 2 migraines per month or subject has more than 15 headache&#xD;
             days/month for any of the 3 months prior ot screening.&#xD;
&#xD;
          -  Subject who has suspected or confirmed cardiovascular disease that contraindicates&#xD;
             study participation.&#xD;
&#xD;
          -  Subject has history of epilepsy or conditions associated with lower seizure threshold.&#xD;
&#xD;
          -  Subject with Raynaud's disease.&#xD;
&#xD;
          -  Subject with hemiplegic or basilar migraine.&#xD;
&#xD;
          -  Subject with a current diagnosis of major depressive disorder.&#xD;
&#xD;
          -  Subject who has taken non-triptan serotonergic drugs including SSRI's, SNRI, TCAs or&#xD;
             MAOI's or preparations containing St. John's Wort within month prior to screening&#xD;
             and/or is planning to start any of these medications during the study and through the&#xD;
             End of Study Visit.&#xD;
&#xD;
          -  Subject is unwilling to discontinue use of PD5 inhibitors (eg. Viagra, Levitra,&#xD;
             Cialis) from screening through End of Study Visit.&#xD;
&#xD;
          -  Subject with a history of significant allergy or hypersensitivity to any component of&#xD;
             the NP101 study patch.&#xD;
&#xD;
          -  Subject who has any generalized skin irritation or disease including eczema,&#xD;
             psoriasis, melanoma, acne or contact dermatitis.&#xD;
&#xD;
          -  Subject has a positive test result for hepatitis B, hepatitis C or is known to be HIV&#xD;
             positive.&#xD;
&#xD;
          -  Subjects with moderate or severe hepatic dysfunction defined as SGOT/AST or SGPT/ALT ≥&#xD;
             2 times the upper limit of normal range, or alkaline phosphatase or total bilirubin ≥&#xD;
             1.5 times the upper limit of normal range or if in the opinion of the investigator,&#xD;
             the subject's history, physical examination or other laboratory tests suggest hepatic&#xD;
             dysfunction.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast feeding, or if not of childbearing potential,&#xD;
             is not using or is unwilling to use an effective form of contraception during the&#xD;
             study and for a period of 30 days following final dosing.&#xD;
&#xD;
          -  Subjects with a known history of tolerability issues with sumatriptan.&#xD;
&#xD;
          -  Subject who is considered by the investigator or NuPathe to be an unsuitable candidate&#xD;
             for this study.&#xD;
&#xD;
          -  Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or&#xD;
             dependence.&#xD;
&#xD;
          -  Subject has participated in a clinical study within 30 days of Screening or is&#xD;
             planning to participate in another clinical study.&#xD;
&#xD;
          -  Subject has clinically significant abnormal labs, vital signs or ECG&#xD;
&#xD;
          -  Subject is electrically sensitive or who has an implantable electronic device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerri L Wilks, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Clinic</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

